ABOUT DATAMONITOR HEALTHCARE 2
About the cardiovascular pharmaceutical analysis team 2
CHAPTER 1 EXECUTIVE SUMMARY 3
Scope of the analysis 3
Datamonitor insight into the cardiovascular market 3
Related reports 5
Upcoming reports 6
CHAPTER 2 MARKET OVERVIEW AND DYNAMICS 8
Seven major markets 8
Regional markets 11
US 11
Japan 12
Five major EU markets 13
Cardiovascular and metabolic markets by disease area 14
Seven major markets 14
Regional markets 16
US 16
Japan 18
Five major EU market 19
Disease focus by mechanism of action 28
Diabetes 29
US 31
Japan 33
Five major EU markets 35
Dyslipidemia 37
US 39
Japan 41
Five major EU markets 43
Hypertension 46
US 48
Japan 50
Five major EU markets 52
Thrombosis 54
US 56
Japan 58
Five major EU markets 60
CHAPTER 3 MARKET FORECASTS 63
Seven major markets 63
Regional markets 67
US 67
Japan 69
Five major EU markets 70
Cardiovascular and metabolic market by disease area 71
Seven major markets 71
Regional markets 73
US 73
Japan 74
Five major EU markets 75
Disease focus by mechanism of action 84
Diabetes 84
US 86
Japan 88
Five major EU markets 90
Dyslipidemia 92
US 94
Japan 95
Five major EU markets 97
Hypertension 98
US 99
Japan 101
Five major EU markets 102
Thrombosis 104
US 106
Japan 107
Five major EU markets 108
CHAPTER 4 MARKET ANALYSIS 111
Leading cardiovascular and metabolic brands 111
Leading cardiovascular and metabolic active agents 114
Company portfolio assessment 118
The top 10 cardiovascular and metabolic companies, 2008 118
Pfizer 118
Sanofi-Aventis 120
Merck-Schering-Plough 122
Novartis 126
Bristol-Myers Squibb 127
Takeda 128
AstraZeneca 129
Novo Nordisk 131
Daiichi Sankyo 131
Abbott 133
Geographical distribution 133
Company vulnerability 135
The forecast top 10 cardiovascular and metabolic companies, 2005-2018 138
BIBLIOGRAPHY 142
APPENDIX A - MARKET ASSUMPTIONS 143
Data definitions, limitations and assumptions 143
Standard units 143
Japanese market data 143
Derivation of sales forecasts and pricing trends 143
Forecasts 144
Forecast methodology 144
Datamonitor reports 144
APPENDIX B -MARKET FORECAST DATA 146
Seven major markets 146
Regional markets 157
US 157
Japan 164
Five major EU markets 169
France 178
Germany 184
Italy 191
Spain 197
UK 203
APPENDIX C 208
Report methodology 208
About Datamonitor 208
About Datamonitor Healthcare 208
Disclaimer 212
List of Tables
Table 1: Cardiovascular and metabolic revenues in the five major EU markets ($m), 2005-08 20
Table 2: Top 25 cardiovascular and metabolic brands in the seven major markets, 2005-2018 113
Table 3: Top 25 cardiovascular and metabolic active agents in the seven major markets, 2005-2018 116
Table 4: Sales forecast for the major cardiovascular and metabolic brands and active agents in the seven major markets ($000s), 2008-2018 146
Table 5: Sales forecast for the major cardiovascular and metabolic brands and active agents in the US ($000s), 2008-2018 157
Table 6: Sales forecast for the major cardiovascular and metabolic brands and active agents in Japan ($000s), 2008-2018 164
Table 7: Sales forecast for the major cardiovascular and metabolic brands and active agents in the five major EU markets ($000s), 2008-2018 169
Table 8: Sales forecast for the major cardiovascular and metabolic brands and active agents in France ($000s), 2008-2018 178
Table 9: Sales forecast for the major cardiovascular and metabolic brands and active agents in Germany ($000s), 2008-2018 184
Table 10: Sales forecast for the major cardiovascular and metabolic brands and active agents in Italy ($000s), 2008-2018 191
Table 11: Sales forecast for the major cardiovascular and metabolic brands and active agents in Spain ($000s), 2008-2018 197
Table 12: Sales forecast for the major cardiovascular and metabolic brands and active agents in the UK ($000s), 2008-2018 203
List of Figures
Figure 1: Cardiovascular and metabolic sales ($ billion) and standard units (SU) sold in the seven major markets, 2005-08 8
Figure 2: Total cardiovascular sales and sales growth in the seven major markets ($ billion), 2005-08 9
Figure 3: Geographical distribution of cardiovascular sales in the seven major markets by value, 2005-08 10
Figure 4: Geographical distribution of cardiovascular units sold (SU) in the seven major markets by volume, 2005-08 10
Figure 5: Total cardiovascular sales and sales growth in the US, 2005-08 12
Figure 6: Total cardiovascular sales and sales growth in Japan ($ billion), 2005-08 13
Figure 7: Total cardiovascular sales and sales growth in the five major EU market ($ billion), 2005-08 14
Figure 8: Cardiovascular and metabolic sales in the seven major markets by disease area, 2008 15
Figure 9: Cardiovascular and metabolic standard units (SU) sold in the seven major markets by disease area, 2008 16
Figure 10: Cardiovascular and metabolic sales in the US ($ billion) by disease area, 2005-08 17
Figure 11: Cardiovascular and metabolic sales in Japan ($ billion) by disease area, 2005-08 18
Figure 12: Cardiovascular and metabolic sales in the five major EU markets ($ billion) by disease area, 2005-08 21
Figure 13: Cardiovascular and metabolic sales in France ($ billion) by disease area, 2005-08 22
Figure 14: Cardiovascular and metabolic sales in Germany ($ billion) by disease area, 2005-08 24
Figure 15: Cardiovascular and metabolic sales in Italy ($ billion) by disease area, 2005-08 25
Figure 16: Cardiovascular and metabolic sales in Spain ($ billion) by disease area, 2005-08 27
Figure 17: Cardiovascular and metabolic sales in the UK ($ billion) by disease area, 2005-08 28
Figure 18: Diabetes sales ($ billion) by leading mechanism of action in the seven major markets, 2005-08 30
Figure 19: Diabetes standard units (SU) sold by leading mechanism of action in the seven major markets, 2005-08 31
Figure 20: Diabetes sales ($ billion) by leading mechanism of action in the US, 2005-08 32
Figure 21: Diabetes standard units (SU) sold by leading mechanism of action in the US, 2005-08 33
Figure 22: Diabetes sales ($ billion) by leading mechanism of action in Japan, 2005-08 34
Figure 23: Diabetes standard units (SU) sold by leading mechanism of action in Japan, 2005-08 35
Figure 24: Diabetes sales ($ billion) by leading mechanism of action in the five major EU markets, 2005-08 36
Figure 25: Diabetes standard units (SU) sold by leading mechanism of action in the five major EU markets, 2005-08 37
Figure 26: Dyslipidemia sales ($ billion) by leading mechanism of action in the seven major markets, 2005-08 38
Figure 27: Dyslipidemia volume use (SU units sold) by leading mechanism of action in the seven major markets, 2005-08 39
Figure 28: Dyslipidemia sales ($ billion) by leading mechanism of action in the US, 2005-08 40
Figure 29: Dyslipidemia standard units (SU) sold by leading mechanism of action in the US, 2005-08 41
Figure 30: Dyslipidemia sales ($ billion) by leading mechanism of action in Japan, 2005-08 42
Figure 31: Dyslipidemia standard units (SU) sold by leading mechanism of action in Japan, 2005-08 43
Figure 32: Dyslipidemia sales ($ billion) by leading mechanism of action in the five major EU markets, 2005-08 44
Figure 33: Dyslipidemia standard units (SU) sold by leading mechanism of action in the five major EU markets, 2005-08 45
Figure 34: Hypertension sales ($ billion) by leading mechanism of action in the seven major markets, 2005-08 47
Figure 35: Hypertension standard units (SU) sold by leading mechanism of action in the seven major markets, 2005-08 48
Figure 36: Hypertension sales ($ billion) by leading mechanism of action in the US, 2005-08 49
Figure 37: Hypertension standard units (SU) sold by leading mechanism of action in the US, 2005-08 50
Figure 38: Hypertension sales ($ billion) by leading mechanism of action in Japan, 2005-08 51
Figure 39: Hypertension standard units (SU) sold by leading mechanism of action in Japan, 2005-08 52
Figure 40: Hypertension sales ($ billion) by leading mechanism of action in the five major EU markets, 2005-08 53
Figure 41: Hypertension standard units (SU) sold by leading mechanism of action in the five major EU markets, 2005-08 54
Figure 42: Antithrombotic sales ($ billion) by leading mechanism of action in the seven major markets, 2005-08 55
Figure 43: Antithrombotic standard units (SU) sold by leading mechanism of action in the seven major markets, 2005-08 56
Figure 44: Antithrombotic sales ($ billion) by leading mechanism of action in the US, 2005-08 57
Figure 45: Antithrombotic standard units (SU) sold by leading mechanism of action in the US, 2005-08 58
Figure 46: Antithrombotic sales ($ billion) by leading mechanism of action in Japan, 2005-08 59
Figure 47: Antithrombotic standard units (SU) sold by leading mechanism of action in Japan, 2005-08 60
Figure 48: Antithrombotic sales ($ billion) by leading mechanism of action in the five major EU markets, 2005-08 61
Figure 49: Antithrombotic standard units (SU) sold by leading mechanism of action in the five major EU markets, 2005-08 62
Figure 50: Forecast cardiovascular and metabolic sales ($ billion) and standard units (SU) sold in the seven major markets, 2008-2018 64
Figure 51: Forecast total cardiovascular and metabolic sales ($ billion) and sales growth in the seven major markets, 2008-2018 65
Figure 52: Geographical distribution of forecast cardiovascular and metabolic sales in the seven major markets, 2008-2018 66
Figure 53: Geographical distribution of forecast cardiovascular and metabolic units sold in the seven major markets, 2008-2018 67
Figure 54: Forecast cardiovascular and metabolic sales ($ billion) and sales growth in the US, 2008-2018 68
Figure 55: Total forecast cardiovascular and metabolic sales ($ billion) and sales growth in Japan, 2008-2018 69
Figure 56: Forecast cardiovascular and metabolic sales ($ billion) and sales growth in the five major EU markets, 2008-2018 71
Figure 57: Forecast cardiovascular and metabolic sales in the seven major markets by disease area, 2018 72
Figure 58: Forecast cardiovascular and metabolic volume use (SU units sold) in the seven major markets by disease area, 2018 73
Figure 59: Forecast cardiovascular and metabolic sales ($ billion) in the US by disease area, 2008-2018 74
Figure 60: Forecast cardiovascular and metabolic sales ($ billion) in Japan by disease area, 2008-2018 75
Figure 61: Forecast cardiovascular and metabolic sales ($ billion) in the five major EU markets by disease area, 2008-2018 76
Figure 62: Forecast cardiovascular and metabolic sales ($ billion) in France by disease area, 2008-18 77
Figure 63: Forecast cardiovascular and metabolic sales ($ billion) in Germany by disease area, 2008-2018 79
Figure 64: Forecast cardiovascular and metabolic sales in Italy ($ billion) by disease area, 2008-2018 81
Figure 65: Forecast cardiovascular and metabolic sales ($ billion) in Spain by disease area, 2008-2018 82
Figure 66: Forecast cardiovascular and metabolic sales ($ billion) in the UK by disease area, 2008-2018 83
Figure 67: Diabetes sales and volume growth by leading mechanism of action in the seven major markets, 2005-08 and 2008-2018 86
Figure 68: Diabetes sales and volume growth by leading mechanisms of action in the US, 2005-08 and 2008-2018 88
Figure 69: Diabetes sales and volume growth by leading mechanism of action in Japan, 2005-08 and 2008-2018 90
Figure 70: Diabetes sales and volume growth by leading mechanism of action in the five major EU markets, 2005-08 and 2008-2018 92
Figure 71: Dyslipidemia sales and volume growth by leading mechanism of action in the seven major markets, 2005-08 and 2008-2018 94
Figure 72: Dyslipidemia sales and volume growth by leading mechanism of action in the US, 2005-08 and 2008-2018 95
Figure 73: Dyslipidemia sales and volume growth by leading mechanism of action in Japan, 2005-08 and 2008-2018 96
Figure 74: Dyslipidemia sales and volume growth by leading mechanism of action in the five major EU markets, 2005-08 and 2008-2018 98
Figure 75: Hypertension sales and volume growth by leading mechanism of action in the seven major markets, 2005-08 and 2008-2018 99
Figure 76: Hypertension sales and volume growth by leading mechanism of action in the US, 2005-08 and 2008-2018 101
Figure 77: Hypertension sales and volume growth by leading mechanism of action in Japan, 2005-08 and 2008-2018 102
Figure 78: Hypertension sales and volume growth by leading mechanism of action in the five major EU markets, 2005-08 and 2008-2018 103
Figure 79: Antithrombotic sales and volume growth by leading mechanism of action in the seven major markets, 2005-08 and 2008-2018 105
Figure 80: Antithrombotic sales and volume growth by leading mechanism of action in the US, 2005-08 and 2008-2018 107
Figure 81: Antithrombotic sales and volume growth by leading mechanism of action in Japan, 2005-08 and 2008-2018 108
Figure 82: Antithrombotic sales and volume growth by leading mechanism of action in the five major EU markets, 2005-08 and 2008-2018 110
Figure 83: Top 10 cardiovascular and metabolic brands in the seven major markets by sales, 2005-2018 112
Figure 84: Decline of the top 10 and top 25 cardiovascular and metabolic brands by sales ($ billion) in the seven major markets, 2005-2018 114
Figure 85: Top 10 cardiovascular and metabolic active agents in the seven major markets by sales, 2005-2018 115
Figure 86: Decline in sales of the top 10 and top 25 cardiovascular and metabolic active agents in the seven major markets, 2005-2018 117
Figure 87: Geographical distribution of sales ($ billion) of the top 10 cardiovascular and metabolic companies, 2008 134
Figure 88: Vulnerability of top 10 cardiovascular and metabolic companies by sales ($ billion) in the seven major markets, 2005-08 136
Figure 89: Cardiovascular and metabolic franchise distribution of the top 10 companies by sales ($ billion) in the seven major markets, 2008 137
Figure 90: Top 10 cardiovascular and metabolic companies in the seven major markets by sales, 2005-2018 138
Figure 91: Forecast branded cardiovascular and metabolic revenues ($ billion) for the top 10 companies in the seven major markets, 2008-2018 139
Figure 92: Forecast branded cardiovascular and metabolic revenues ($ billion) of AstraZeneca, Bristol-Myers Squibb, Novo Nordisk and Pfizer in the seven major markets, 2008-2018 140
Figure 93: Forecast branded cardiovascular and metabolic revenues ($ billion) for Sanofi-Aventis and Merck-Schering-Plough in the seven major markets, 2008-2018 141
